Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.73 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.73 |
| ▸ | FPR1 | P21462 | 1/20 | 0.73 |
| ▸ | FPR3 | P25089 | 1/20 | 0.73 |
| ▸ | GPR183 | P32249 | 1/20 | 0.73 |
| ▸ | APLNR | P35414 | 1/20 | 0.73 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551097 | 0.90 | FFAR1 (0.74) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551130 | 0.86 | FFAR1 (0.71) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550669 | 0.86 | FFAR1 (0.68) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551222 | 0.85 | FFAR1 (0.71) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551263 | 0.85 | FFAR1 (0.79) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551624 | 0.85 | FFAR1 (0.74) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550802 | 0.85 | FFAR1 (0.71) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551069 | 0.85 | FFAR1 (0.72) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551461 | 0.85 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL29358680 | 0.85 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| EP-2313360-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885FFAR4 12/4885CHRM2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.